RANDAL SCHOLMA: Open Payments
NPI 1558574566 · LOWELL, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$29,308 in 127 payments from 13 companies in 2025. Trend: 2023 $13,076 · 2024 $15,672 · 2025 $29,308
Honoraria: $22,039Food & beverage: $3,143Speaker / faculty: $2,250Travel & lodging: $1,793Education: $84
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 32 | $24,925 |
| ABBVIE INC. | 19 | $2,589 |
| Alkermes, Inc. | 18 | $458 |
| Teva Pharmaceuticals USA, Inc. | 8 | $252 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $212 |
| Neurocrine BioSciences, Inc. | 9 | $206 |
| Vanda Pharmaceuticals Inc. | 6 | $157 |
| Janssen Pharmaceuticals, Inc | 5 | $111 |
| E.R. Squibb & Sons, L.L.C. | 5 | $106 |
| Corium, LLC | 4 | $103 |
Products named: Auvelity, VRAYLAR, ARISTADA, CAPLYTA, INGREZZA, AUSTEDO XR, REXULTI, HETLIOZ.
Industry payments across AR — which companies pay providers there.
